Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26700952 | 0.95 | NAMPT (0.47) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL13599210 | 0.95 | NAMPT (0.47) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL26700954 | 0.95 | NAMPT (0.47) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL23729307 | 0.95 | NAMPT (0.47) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL16248541 | 0.95 | NAMPT (0.47) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL24935691 | 0.95 | NAMPT (0.47) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL26700957 | 0.93 | NAMPT (0.45) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL26818739 | 0.93 | LMNA (0.44) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL16843241 | 0.92 | CASP2 (0.44) | NAMPTFAAHLMNAPKMALDH1A1 | |
| SCHEMBL16692591 | 0.89 | ALDH1A1 (0.46) | NAMPTFAAHLMNAPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20220168430-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (US) | 2022-06-02 | — | — | US | disclosed |
| US-20200407724-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-12-31 | — | — | US | disclosed |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | NAMPT 558/4885FAAH 4049/4885LMNA 454/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | NAMPT 1638/4885FAAH 3562/4885LMNA 145/4885 |
| US-20220168430-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | HAVCR2, HDGF, FABP1 | NAMPT 1099/4885FAAH 1624/4885LMNA 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.